Granules gets Health Canada nod for arthritis drug Acetaminophen ER tablets
Hyderabad: Granules India Limited has recently announced that the company has received marketing approval from Health Canada for Acetaminophen Extended-Release Tablets OTC, 650mg for the treatment of Arthritis Pain.
The product manufactured by Granules is a bioequivalent to the reference listed drug, Tylenol Extended Release 650 Tablets.
Priyanka Chigurupati, Executive Director of Granules USA, Inc. & Granules Pharmaceuticals, Inc. said, "We received the approval within eight months of filing. This is a step towards global expansion of our core molecules. The approval of Acetaminophen Extended-Release Tablets OTC, 650mg, a complex Bi-layer Extended Released based formulations, is a good addition to our portfolio. We will be launching the product in the Canada market soon."
The drug will be manufactured at the Granules manufacturing facility located in Gagillapur, Hyderabad. Granules now have a total of 2 ANDS approvals from Health Canada.
Read also: Granules India arm clears USFDA audit
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.